Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
The FDA removed the clinical hold on Arbutus Biopharma's IND for AB-101, an oral PD-L1 inhibitor for chronic hepatitis B, allowing renewed U.S. clinical development. Phase 1a/1b data showed AB-101 was generally well-tolerated, with high receptor occupancy in seven cHBV patients and HBsAg decline in two patients at the 30mg dose.
Key figures
- Drug Name
- AB-101
- Phase Of Trial
- Phase 1a/1b completed
- Hbsag decline dose
- 30mg
- Hbsag decline patients
- 2
- Receptor occupancy patients
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.